Related Experiment Videos
Regulation of human tumor antigen expression by biological response modifiers (BRMs)
F Guadagni1, M Roselli, J Schlom
1Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Abstract:
The ongoing development of monoclonal antibody technology may eventually lead to the selective targeting of human carcinoma lesions of MoAbs conjugated with a variety of cytotoxic agents (i.e. radionuclides, drugs, etc.). The antigen phenotype of the carcinoma cell will play an important role in the efficacy of the MoAbs. Clearly, the human tumor antigens that are expressed on all carcinoma cells and with a high antigen density should provide the optimal target for the MoAbs. More often, however, the human tumor antigens whose expression is highly selective for human tumor cells will also exhibit a certain degree of heterogeneity. Therefore, the ability of a cytokine, such as interferon or 8-Cl-cAMP, to augment the level of expression of human tumor antigens such as TAG-72 and CEA, may play an important role in an adjuvant setting for immunoscintigraphy and/or immunotherapy. Further research will focus on experimental model system as well as clinical trials to determine whether human recombinant interferon administered with an anti-carcinoma MoAb will be an effective combination to enhance tumor detection and/or therapy. It is conceivable that in subsequent years effective approaches of treating malignancies may include a new combination of biological/immunological therapy based on the biology of the tumor cell population.
Insights
Monoclonal antibodies (MoAbs) conjugated with cytotoxic agents show promise for targeting human carcinoma. Cytokines like interferon may enhance tumor antigen expression, improving detection and therapy for malignancies.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Monoclonal antibody (MoAb) technology is advancing for targeted cancer therapy.
- Carcinoma antigen phenotype influences MoAb efficacy, with high-density antigens being optimal targets.
- Tumor antigen expression can be heterogeneous, necessitating strategies to enhance target recognition.
Purpose of the Study:
- To explore the potential of MoAbs conjugated with cytotoxic agents for targeting human carcinoma.
- To investigate the role of cytokines, such as interferon, in augmenting tumor antigen expression (e.g., TAG-72, CEA).
- To evaluate the combination of interferon and anti-carcinoma MoAbs for enhanced tumor detection and immunotherapy.
Main Methods:
- Review of monoclonal antibody technology development for cancer treatment.
- Discussion of tumor antigen expression and heterogeneity in carcinomas.
- Consideration of cytokine-mediated augmentation of tumor antigens like TAG-72 and CEA.
- Focus on experimental models and clinical trials for interferon and MoAb combinations.
Main Results:
- Monoclonal antibodies conjugated with cytotoxic agents offer selective targeting of carcinoma lesions.
- Cytokines can increase the expression of tumor antigens, potentially aiding immunoscintigraphy and immunotherapy.
- Combination therapy with interferon and anti-carcinoma MoAbs is being investigated for improved tumor detection and treatment efficacy.
Conclusions:
- Targeting carcinoma with MoAbs is a developing field, influenced by antigen expression.
- Cytokine-induced enhancement of tumor antigens presents a promising adjuvant strategy.
- Future cancer treatment may involve novel combinations of biological and immunological therapies tailored to tumor biology.